UPDATE 1-U.S. approves GSK, Xenoport drug for new use
LONDON, June 7
LONDON, June 7 (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday.
The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use.
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Russia can run on empty for a year if sanctions block new bonds
- Mumbai hit by big power cuts after technical glitch at Tata Power unit
- Rupee sees biggest fall in three weeks on broad dollar gains
- 100 days of Modi: Good for business, not so good for marginalised groups